STAT

International trial uses AI to rapidly identify optimal Covid-19 treatments

A major study seeks to turn frenetic attempts to save lives into a running international experiment, with the goal of quickly identifying optimal treatments for #coronavirus patients.
Source: Gene J. Puskar/AP

Treating patients with the never-before-seen Covid-19 is forcing doctors to choose between two equally unpalatable options: try an unproven therapy and hope it works, or treat patients with standard supportive care for severe respiratory disease until a randomized controlled trial establishes the best treatment.

But maybe the choice doesn’t have to be so stark.

A randomized controlled trial ramping up in dozens of hospitals around the world proposes a third way — fusing those two approaches together by using artificial intelligence to home in on the most effective treatments on the fly.

The study seeks to turn frenetic attempts to save is an effective therapy and, if so, for which types of patients. The trial will also allow the researchers to test multiple therapies at once.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks